அறிகுறி முன்னேற்றம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அறிகுறி முன்னேற்றம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அறிகுறி முன்னேற்றம் Today - Breaking & Trending Today

Surface Ophthalmics' Landmark Chronic Dry Eye Study Reaches 50% Enrollment Milestone


Surface Ophthalmics Landmark Chronic Dry Eye Study Reaches 50% Enrollment Milestone
First-ever head-to-head study in chronic dry eye disease, comparing SURF-100 against leading on-market competitors lifitegrast ophthalmic solution 5% and cyclosporine ophthalmic emulsion 0.05%
News provided by
Share this article
Share this article
PLEASANTON, Calif., May 6, 2021 /PRNewswire/  Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, today announced that 50% of patients have been enrolled and randomized in the Phase II clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity
® vehicle) for the treatment of chronic dry eye disease. Having reached this milestone, the company is on track to announce top-line results from the trial in the first quarter of 2022.   ....

United States , Richardl Lindstrom , Kamran Hosseini , University Of North Carolina , Surface Ophthalmics Inc , Surface Ophthalmics , Symptom Improvement , North Carolina , Dry Eye Management Scale , Surface Ophthalmic , ஒன்றுபட்டது மாநிலங்களில் , கம்ரான் ஹொசைனி , பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா , மேற்பரப்பு கண் மருத்துவம் இன்க் , மேற்பரப்பு கண் மருத்துவம் , அறிகுறி முன்னேற்றம் , வடக்கு கரோலினா , மேற்பரப்பு கண் ,

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years


Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. ....

United States , University Of Washington , Spring House , British Columbia , Jennifer Mcintyre , Alyssa Johnsen , Philipj Mease , Christopher Delorefice , Bridget Kimmel , Zismand Comorbidities , American College Of Rheumatology , Department Of Medicine Division Rheumatology , Janssen Research Development , Janssen Pharmaceutical Companies , Health Qual Life Outcomes , Janssen Pharmaceutical Companies Of Johnson , Everyday Health , National Psoriasis Foundation , Swedish Medical Center Providence St , None Of The Janssen Pharmaceutical Companies , Joseph Health , Drug Administration , Arthritis Research Therapy , Exchange Commission , Virtual Spring Conference , Swedish Medical ,

Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye


Published: Feb 04, 2021
 
PLEASANTON, Calif., Feb. 4, 2021 /PRNewswire/  Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, today announced that the first patient has been dosed in the Phase II clinical trial for its investigational product SURF-200 (betamethasone in Klarity® vehicle) for the treatment of acute dry eye.  
In this dose-ranging study, SURF-200 will be studied in two different low concentration formulations which include betamethasone, a corticosteroid with a strong track record in global use but is now making its debut in the ocular space in the United States, in the Klarity vehicle. SURF-200 has been formulated to provide comparable efficacy with an improved safety and tolerability profile when compared to currently used steroids. The trial will enroll between 120-140 patients with a primary endpoint of Symptom Improvement of one unit based on th ....

United States , Richardl Lindstrom , Kamran Hosseini , Preeya Gupta , Surface Ophthalmics Inc , Surface Ophthalmics , Symptom Improvement , North Carolina Dry Eye Management Scale , Associate Professor , Duke University Eye Center , Surface Ophthalmic , ஒன்றுபட்டது மாநிலங்களில் , கம்ரான் ஹொசைனி , பிரீயா குப்தா , மேற்பரப்பு கண் மருத்துவம் இன்க் , மேற்பரப்பு கண் மருத்துவம் , அறிகுறி முன்னேற்றம் , வடக்கு கரோலினா உலர்ந்த கண் மேலாண்மை அளவு , இணை ப்ரொஃபெஸர் , டியூக் பல்கலைக்கழகம் கண் மையம் , மேற்பரப்பு கண் ,